The global high potency active pharmaceutical ingredients market size is expected to reach USD 40.66 billion by 2030 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030. The growth of the HPAPI market is attributed to rising incidence of cancer, growing targeted therapies, and increasing application of high potency active pharmaceutical ingredients (HPAPI) in treating target diseases. Rising prevalence of cancer is expected to be a major factor. According to the WHO, cancer is the second leading cause of death, accounting for around 9.9 million deaths in 2020. Due to the growing number of people who contract the disease, cancer is regarded as one of the major health risks. The CDC states that factors such as smoking, obesity, alcohol use, and UV radiation exposure are risk factors for cancer since they contribute to the overall burden of the illness.
With limited treatment options and side effects associated with chemotherapy, there is a rising popularity of targeted therapy as it does not damage non-cancerous cells. In May 2021, Amgen, Inc. received the U.S. FDA approval for the launch of LUMAKRAS for treating patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. LUMAKRAS is the first targeted product for the treatment of G12C-mutated KRAS NSCLC patients. This is likely to increase the demand for HPAPIs in the coming years. Characteristics of these anti-cancerous drugs, such as minimum exposure of drugs to non-cancerous cell and their effectiveness, are contributing to market growth.
The proprietary technology of companies, such as drug designing & delivery technology helps develop novel treatment and HPAPI alternatives through collaborations with other key players, which may increase the number of research initiatives. For instance, in November 2021, the company launched a novel technology ChetoSensar to enhance the development of Antibody-Drug Conjugates (ADCs) therapies. This initiative is aimed at significantly doubling the company’s efforts to boost its production of HPAPIs and ADCs.
Moreover,a closed containment facility is needed to manufacture HPAPIs because they are complex substances. To sustain continuous production, generic manufacturers are investing in the development of their facilities for manufacturing and technology improvements within these facilities, which is anticipated to propel the growth of the generic medication market throughout the course of the forecast period. Furthermore, key players operating in the HPAPI market are focusing on expanding. For instance, in March 2022, Lonza announced the laboratory expansion completion for its Nansha, China facility. The expansion was aimed at capacity enhancement of its small scale facilities for CGMP production of high potency APIs.
With limited treatment options and side effects associated with chemotherapy, there is a rising popularity of targeted therapy as it does not damage non-cancerous cells. In May 2021, Amgen, Inc. received the U.S. FDA approval for the launch of LUMAKRAS for treating patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. LUMAKRAS is the first targeted product for the treatment of G12C-mutated KRAS NSCLC patients. This is likely to increase the demand for HPAPIs in the coming years. Characteristics of these anti-cancerous drugs, such as minimum exposure of drugs to non-cancerous cell and their effectiveness, are contributing to market growth.
The proprietary technology of companies, such as drug designing & delivery technology helps develop novel treatment and HPAPI alternatives through collaborations with other key players, which may increase the number of research initiatives. For instance, in November 2021, the company launched a novel technology ChetoSensar to enhance the development of Antibody-Drug Conjugates (ADCs) therapies. This initiative is aimed at significantly doubling the company’s efforts to boost its production of HPAPIs and ADCs.
Moreover,a closed containment facility is needed to manufacture HPAPIs because they are complex substances. To sustain continuous production, generic manufacturers are investing in the development of their facilities for manufacturing and technology improvements within these facilities, which is anticipated to propel the growth of the generic medication market throughout the course of the forecast period. Furthermore, key players operating in the HPAPI market are focusing on expanding. For instance, in March 2022, Lonza announced the laboratory expansion completion for its Nansha, China facility. The expansion was aimed at capacity enhancement of its small scale facilities for CGMP production of high potency APIs.
High Potency Active Pharmaceutical Ingredients Market
- In 2022, synthetic segment held a dominant share in the HPAPI market owing to its easier synthesis and effectiveness in treatment offered by synthetic HPAPI
- Outsourced segment is projected to grow at the fastest rate over the forecast period owing to the increasing adoption of outsourcing of HPAPI
- Innovative HPAPI segment is the highest revenue-generating segment in 2022 owing to the increased focus on R&D.
- Oncology segment dominated the overall market owing to the rising cancer incidence worldwide along with an enhanced focus on targeted therapies
- Asia Pacific is expected to witness the fastest growth during the forecast period owing to the improved manufacturing facilities and the availability of many generic HPAPI producers
Table of Contents
Chapter 1 Methodology and Scope1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
1.6.1.3 Approach 2: Country wise market estimation using top down approach
1.7 Global Market: CAGR Calculation
1.8 List of Secondary Sources
1.9 Objectives
1.9.1 Objective 1:
1.9.2 Objective 2:
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 High Potency Active Pharmaceutical Ingredients Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Rising prevalence of cancer
3.3.1.2 Growth of targeted therapies
3.3.1.3 Increasing application of HPAPI
3.3.2 Market Restraint Analysis
3.3.2.1 Large investments and very stringent safety and handling specifications associated with production of HPAPI
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis - Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 High Potency Active Pharmaceutical Ingredients Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2022
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)
5.1 Definition and Scope
5.2 Product Market Share Analysis, 2022 & 2030
5.3 Global High Potency Active Pharmaceutical Ingredients Market, By Product, 2018 To 2030
5.4 High Potency Active Pharmaceutical Ingredients Market: Product Movement Analysis
5.5 Synthetic
5.5.1 Synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
5.6 Biotech
5.6.1 Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6 High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Type of Manufacturer, 2018 - 2030 (USD Million)
6.1 Definition and Scope
6.2 Type of Manufacturer Market Share Analysis, 2022 & 2030
6.3 Global High Potency Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2018 To 2030
6.4 High Potency Active Pharmaceutical Ingredients Market: Type of Manufacturer Movement Analysis
6.5 In-house
6.5.1 In-house market estimates and forecasts, 2018 - 2030 (USD Million)
6.6 Outsourced
6.6.1 Outsourced market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7 High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Drug Type, 2018 - 2030 (USD Million)
7.1 Definition and Scope
7.2 Drug Type Market Share Analysis, 2022 & 2030
7.3 Global High Potency Active Pharmaceutical Ingredients Market, By Drug Type, 2018 To 2030
7.4 High Potency Active Pharmaceutical Ingredients Market: Therapy Movement Analysis
7.5 Innovative
7.5.1 Innovative market estimates and forecasts, 2018 - 2030 (USD Million)
7.6 Generic
7.6.1 Generic market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8 High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)
8.1 Definition and Scope
8.2 Therapy Market Share Analysis, 2022 & 2030
8.3 Global High Potency Active Pharmaceutical Ingredients Market, By Therapy, 2018 To 2030
8.4 High Potency Active Pharmaceutical Ingredients Market: Therapy Movement Analysis
8.5 Oncology
8.5.1 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
8.6 Hormonal Disorders
8.6.1 Hormonal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
8.7 Glaucoma
8.7.1 Glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
8.8 Other Therapeutic Applications
8.8.1 Other therapeutic applications market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9 High Potency Active Pharmaceutical Ingredients Market: Regional Business Analysis
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2022 & 2030
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
9.5.1 North America
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Latin America
9.5.5 MEA
9.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
9.7 North America
9.7.1 North America High Potency Active Pharmaceutical Ingredients Market Estimates And Forecast, 2018 - 2030 (USD Million)
9.7.2 U.S.
9.7.2.1 U.S. high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.7.2.2 Key Country Dynamics
9.7.2.3 Regulatory Framework
9.7.2.4 Competitive Scenario
9.7.3 Canada
9.7.3.1 Canada high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.7.3.2 Key Country Dynamics
9.7.3.3 Regulatory Framework
9.7.3.4 Competitive Scenario
9.8 Europe
9.8.1 Europe High Potency Active Pharmaceutical Ingredients Market, 2018 - 2030 (USD Million)
9.8.2 U.K.
9.8.2.1 U.K. high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.8.2.2 Key Country Dynamics
9.8.2.3 Regulatory Framework
9.8.2.4 Competitive Scenario
9.8.3 Germany
9.8.3.1 Germany high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.8.3.2 Key Country Dynamics
9.8.3.3 Regulatory Framework
9.8.3.4 Competitive Scenario
9.8.4 Spain
9.8.4.1 Spain high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.8.4.2 Key Country Dynamics
9.8.4.3 Regulatory Framework
9.8.4.4 Competitive Scenario
9.8.5 France
9.8.5.1 France high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.8.5.2 Key Country Dynamics
9.8.5.3 Regulatory Framework
9.8.5.4 Competitive Scenario
9.8.6 Italy
9.8.6.1 Italy high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.8.6.2 Key Country Dynamics
9.8.6.3 Regulatory Framework
9.8.6.4 Competitive Scenario
9.8.7 Norway
9.8.7.1 Norway high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.8.7.3 Regulatory Framework
9.8.7.4 Competitive Scenario
9.8.8 Denmark
9.8.8.1 Denmark high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.8.8.2 Key Country Dynamics
9.8.8.3 Regulatory Framework
9.8.8.4 Competitive Scenario
9.8.9 Sweden
9.8.9.1 Sweden high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.8.9.2 Key Country Dynamics
9.8.9.3 Regulatory Framework
9.8.9.4 Competitive Scenario
9.9 Asia Pacific
9.9.1 Asia-Pacific High Potency Active Pharmaceutical Ingredients Market, 2018 - 2030 (USD Million)
9.9.2 Japan
9.9.2.1 Japan high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.9.2.2 Key Country Dynamics
9.9.2.3 Regulatory Framework
9.9.2.4 Competitive Scenario
9.9.3 China
9.9.3.1 China high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.9.3.2 Key Country Dynamics
9.9.3.3 Regulatory Framework
9.9.3.4 Competitive Scenario
9.9.4 India
9.9.4.1 India high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.9.4.2 Key Country Dynamics
9.9.4.3 Regulatory Framework
9.9.4.4 Competitive Scenario
9.9.5 South Korea
9.9.5.1 South Korea high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.9.5.2 Key Country Dynamics
9.9.5.3 Regulatory Framework
9.9.5.4 Competitive Scenario
9.9.6 Thailand
9.9.6.1 Thailand high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.9.6.2 Key Country Dynamics
9.9.6.3 Regulatory Framework
9.9.6.4 Competitive Scenario
9.9.7 Australia
9.9.7.1 Australia high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.9.7.2 Key Country Dynamics
9.9.7.3 Regulatory Framework
9.9.7.4 Competitive Scenario
9.10 Latin America
9.10.1 Latin America High Potency Active Pharmaceutical Ingredients Market, 2018 - 2030 (USD Million)
9.10.2 Brazil
9.10.2.1 Brazil high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.10.2.2 Key Country Dynamics
9.10.2.3 Regulatory Framework
9.10.2.4 Competitive Scenario
9.10.3 Mexico
9.10.3.1 Mexico high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.10.3.2 Key Country Dynamics
9.10.3.3 Regulatory Framework
9.10.3.4 Competitive Scenario
9.10.4 Argentina
9.10.4.1 Argentina high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.10.4.2 Key Country Dynamics
9.10.4.3 Regulatory Framework
9.10.4.4 Competitive Scenario
9.11 MEA
9.11.1 MEA High Potency Active Pharmaceutical Ingredients Market, 2018 - 2030 (USD Million)
9.11.2 South Africa
9.11.2.1 South Africa high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.11.2.2 Key Country Dynamics
9.11.2.3 Regulatory Framework
9.11.2.4 Competitive Scenario
9.11.3 Saudi Arabia
9.11.3.1 Saudi Arabia high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.11.3.2 Key Country Dynamics
9.11.3.3 Regulatory Framework
9.11.3.4 Competitive Scenario
9.11.4 UAE
9.11.4.1 UAE high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.11.4.2 Key Country Dynamics
9.11.4.3 Regulatory Framework
9.11.4.4 Competitive Scenario
9.11.5 Kuwait
9.11.5.1 Kuwait high potency active pharmaceutical ingredients market, 2018 - 2030 (USD Million)
9.11.5.2 Key Country Dynamics
9.11.5.3 Regulatory Framework
9.11.5.4 Competitive Scenario
Chapter 10 High Potency Active Pharmaceutical Ingredients Market: Company Profiles
10.1 Company Profiles
10.1.1 BASF SE
10.1.1.1 Company Overview
10.1.1.2 Financial Performance
10.1.1.3 Product Benchmarking
10.1.1.4 Strategic Initiatives
10.1.2 CordenPharma International
10.1.2.1 Company Overview
10.1.2.3 Strategic Initiatives
10.1.3 Dr. Reddy’s Laboratories Ltd.
10.1.3.1 Company Overview
10.1.3.2 Financial Performance
10.1.3.3 Product Benchmarking
10.1.3.4 Strategic Initiatives
10.1.4 Carbogen Amcis AG
10.1.4.1 Company Overview
10.1.4.2 Financial Performance
10.1.4.3 Product Benchmarking
10.1.4.4 Strategic Initiatives
10.1.5 Pfizer Inc.
10.1.5.1 Company Overview
10.1.5.2 Financial Performance
10.1.5.3 Product Benchmarking
10.1.5.4 Strategic Initiatives
10.1.6 Sun Pharmaceutical Industries Ltd.
10.1.6.1 Company Overview
10.1.6.2 Financial Performance
10.1.6.3 Product Benchmarking
10.1.6.4 Strategic Initiatives
10.1.7 Teva Pharmaceutical Industries Ltd.
10.1.7.1 Company Overview
10.1.7.2 Financial Performance
10.1.7.3 Product Benchmarking
10.1.7.4 Strategic Initiatives
10.1.8 Albany Molecular Research Inc.
10.1.8.1 Company Overview
10.1.8.2 Product Benchmarking
10.1.8.3 Strategic Initiatives
10.1.9 Sanofi
10.1.9.1 Company Overview
10.1.9.2 Financial Performance
10.1.9.3 Product Benchmarking
10.1.9.4 Strategic Initiatives
10.1.10 Merck & Co., Inc.
10.1.10.1 Company Overview
10.1.10.2 Financial Performance
10.1.10.3 Product Benchmarking
10.1.10.4 Strategic Initiatives
10.1.11 Novartis AG
10.1.11.1 Company Overview
10.1.11.2 Financial Performance
10.1.11.3 Product Benchmarking
10.1.11.4 Strategic Initiatives
10.1.12 F. Hoffmann-La Roche Ltd.
10.1.12.1 Company Overview
10.1.12.2 Financial Performance
10.1.12.3 Product Benchmarking
10.1.12.4 Strategic Initiatives
10.1.13 Bristol-Myers Squibb Company
10.1.13.1 Company Overview
10.1.13.2 Financial Performance
10.1.13.3 Product Benchmarking
10.1.13.4 Strategic Initiatives
10.1.14 Boehringer Ingelheim GmbH
10.1.14.1 Company Overview
10.1.14.2 Financial Performance
10.1.14.3 Product Benchmarking
10.1.14.4 Strategic Initiatives
10.1.15 Lonza
10.1.15.1 Company Overview
10.1.15.2 Financial Performance
10.1.15.3 Product Benchmarking
10.1.15.4 Strategic Initiatives
10.1.16 Cipla Inc.
10.1.16.1 Company Overview
10.1.16.2 Financial Performance
10.1.16.3 Product Benchmarking
10.1.16.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Regulatory Framework
TABLE 4 Global HPAPI market, by region, 2018 - 2030 (USD Million)
TABLE 5 Global HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 6 Global HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 7 Global HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 8 Global HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 9 North America HPAPI market, by country, 2018 - 2030 (USD Million)
TABLE 10 North America HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 11 North America HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 12 North America HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 13 North America HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 14 U.S. HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 15 U.S. HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 16 U.S. HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 17 U.S. HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 18 Canada HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 19 Canada HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 20 Canada HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 21 Canada HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 22 Europe HPAPI market, 2018 - 2030 (USD Million)
TABLE 23 Europe HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 24 Europe HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 25 Europe HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 26 Europe HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 27 U.K. HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 28 U.K. HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 29 U.K. HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 30 U.K. HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 31 Germany HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 32 Germany HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 33 Germany HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 34 Germany HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 35 Spain HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 36 Spain HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 37 Spain HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 38 Spain HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 39 France HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 40 France HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 41 France HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 42 France HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 43 Italy HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 44 Italy HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 45 Italy HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 46 Italy HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 47 Denmark HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 48 Denmark HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 49 Denmark HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 50 Denmark HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 51 Sweden HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 52 Sweden HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 53 Sweden HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 54 Sweden HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 55 Norway HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 56 Norway HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 57 Norway HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 58 Norway HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 59 Asia Pacific HPAPI market, 2018 - 2030 (USD Million)
TABLE 60 Asia Pacific HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 61 Asia Pacific HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 62 Asia Pacific HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 63 Asia Pacific HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 64 Japan HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 65 Japan HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 66 Japan HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 67 Japan HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 68 China HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 69 China HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 70 China HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 71 China HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 72 India market, by product, 2018 - 2030 (USD Million)
TABLE 73 India HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 74 India HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 75 India HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 76 Australia market, by product, 2018 - 2030 (USD Million)
TABLE 77 Australia HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 78 Australia HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 79 Australia HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 80 Thailand HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 81 Thailand HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 82 Thailand HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 83 Thailand HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 84 South Korea market, by product, 2018 - 2030 (USD Million)
TABLE 85 South Korea HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 86 South Korea HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 87 South Korea HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 88 Latin America HPAPI market, 2018 - 2030 (USD Million)
TABLE 89 Latin America HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 90 Latin America HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 91 Latin America HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 92 Latin America HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 93 Brazil HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 94 Brazil HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 95 Brazil HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 96 Brazil HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 97 Mexico HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 98 Mexico HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 99 Mexico HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 100 Mexico HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 101 Argentina HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 102 Argentina HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 103 Argentina HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 104 Argentina HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 105 MEA HPAPI market, 2018 - 2030 (USD Million)
TABLE 106 MEA HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 107 MEA HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 108 MEA HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 109 MEA HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 110 South Africa HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 111 South Africa HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 112 South Africa HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 113 South Africa HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 114 Saudi Arabia HPAPI market, by product, 2018 - 2030, (USD Million)
TABLE 115 Saudi Arabia HPAPI market, by drug type, 2018 - 2030, (USD Million)
TABLE 116 Saudi Arabia HPAPI market, by manufacturer type, 2018 - 2030, (USD Million)
TABLE 117 Saudi Arabia HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 118 UAE HPAPI market, by product, 2018 - 2030, (USD Million)
TABLE 119 UAE HPAPI market, by drug type, 2018 - 2030, (USD Million)
TABLE 120 UAE HPAPI market, by manufacturer type, 2018 - 2030, (USD Million)
TABLE 121 UAE HPAPI market, by application, 2018 - 2030 (USD Million)
TABLE 122 Kuwait HPAPI market, by product, 2018 - 2030 (USD Million)
TABLE 123 Kuwait HPAPI market, by drug type, 2018 - 2030 (USD Million)
TABLE 124 Kuwait HPAPI market, by manufacturer type, 2018 - 2030 (USD Million)
TABLE 125 Kuwait HPAPI market, by application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 High Potency Active Pharmaceutical Ingredients (HPAPI) market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modeling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Primary interviews, by sources
FIG. 10 Primary interviews, by region
FIG. 11 High potency active pharmaceutical ingredients market summary
FIG. 12 Market driver relevance analysis (Current & future impact)
FIG. 13 Estimated number of cancer cases (5 year) worldwide
FIG. 14 New cases of cancer worldwide (2022)
FIG. 15 High potency active pharmaceutical ingredients market restraint impact
FIG. 16 Penetration and growth prospect mapping
FIG. 17 User perspective analysis
FIG. 18 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 19 Porter’s five forces analysis
FIG. 20 High potency active pharmaceutical ingredients product outlook: Key takeaways
FIG. 21 High potency active pharmaceutical ingredients market: Product movement analysis
FIG. 22 Synthetic market, 2018 - 2030 (USD Million)
FIG. 23 Biotech market, 2018 - 2030 (USD Million)
FIG. 24 High potency active pharmaceutical ingredients market type of manufacturer outlook: Key takeaways
FIG. 25 High potency active pharmaceutical ingredients market: Type of manufacturer movement analysis
FIG. 26 In-house market, 2018 - 2030 (USD Million)
FIG. 27 Outsourced market, 2018 - 2030 (USD Million)
FIG. 28 High potency active pharmaceutical ingredients market application outlook: Key takeaways
FIG. 29 High potency active pharmaceutical ingredients market: Drug type movement analysis
FIG. 30 Innovative market, 2018 - 2030 (USD Million)
FIG. 31 Generic market, 2018 - 2030 (USD Million)
FIG. 32 High potency active pharmaceutical ingredients market therapeutic application outlook: Key takeaways
FIG. 33 High potency active pharmaceutical ingredients market: Therapeutic application movement analysis
FIG. 34 Oncology market, 2018 - 2030 (USD Million)
FIG. 35 Hormonal disorders market, 2018 - 2030 (USD Million)
FIG. 36 Glaucoma market, 2018 - 2030 (USD Million)
FIG. 37 Other therapeutic applications market, 2018 - 2030 (USD Million)
FIG. 38 Regional marketplace: Key takeaways
FIG. 39 Regional outlook, 2022 & 2030
FIG. 40 North America
FIG. 41 North America. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 42 U.S.
FIG. 43 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 44 Canada
FIG. 45 Canada market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 46 Europe
FIG. 47 Europe market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 48 U.K.
FIG. 49 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 50 Germany
FIG. 51 Germany market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 52 France
FIG. 53 France market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 54 Spain
FIG. 55 Spain market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 56 Italy
FIG. 57 Italy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 58 Denmark
FIG. 59 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 60 Sweden
FIG. 61 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 62 Norway
FIG. 63 Norway market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 64 Asia-Pacific
FIG. 65 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 66 Japan
FIG. 67 Japan market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 68 China
FIG. 69 China market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 70 India
FIG. 71 India market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 72 Australia
FIG. 73 Australia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 74 Thailand
FIG. 75 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 76 South Korea
FIG. 77 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 78 Latin America
FIG. 79 Latin America. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 80 Brazil
FIG. 81 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 82 Mexico
FIG. 83 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 84 Argentina
FIG. 85 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 86 Middle East & Africa
FIG. 87 MEA market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 88 South Africa
FIG. 89 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 90 Saudi Arabia
FIG. 91 Saudi Arabia market estimates and forecast, 2018- 2030, USD Million
FIG. 92 UAE
FIG. 93 UAE market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 94 Kuwait
FIG. 95 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 96 Ansoff Matrix
FIG. 97 Strategy mapping
FIG. 98 Company/Competition Categorization
FIG. 99 Heat Map Analysis
FIG. 100 Regional Network Map
Companies Mentioned
- BASF SE
- CordenPharma International
- Dr. Reddy’s Laboratories Ltd.
- Carbogen Amcis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Albany Molecular Research Inc.
- Sanofi
- Merck & Co., Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Lonza
- Cipla Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 191 |
| Published | March 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 25.17 Billion |
| Forecasted Market Value ( USD | $ 40.66 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
